Substance / Medication

Denosumab

Overview

Active Ingredient
denosumab
RxNorm CUI
993449
Labeler: CELLTRION USA, Inc.Updated: 2026-01-20T00:00:00.000ZFull label on DailyMed

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

38 trials linked to this intervention

38
Total Trials
18
Recruiting
8
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Beyond bone effects: the role of denosumab in muscle Health - A systematic review.
Ceolin Chiara, Ziliotto Chiara, Papa Mario Virgilio et al. · Aging Clin Exp Res · 2026
PMID: 41511732Meta-AnalysisFull text (PMC)
Efficacy and safety of denosumab in treatment of osteoporosis in patients with rheumatoid arthritis: a meta-analysis and systematic review.
Zhang Runyao, Kou Nannan, Liu Feifei et al. · BMC Musculoskelet Disord · 2025
PMID: 41068709Meta-AnalysisFull text (PMC)
Cost-Effectiveness of Denosumab for Treating Bone Metastases from Solid Tumors: A Systematic Review (2017-2023).
Wang Cong, Liu Jin-Yu, Wan Min et al. · Chin Med Sci J · 2025
PMID: 41099186Meta-Analysis
Effects of Bisphosphonates and Denosumab on Dental Implants: A Systematic Review With Meta-Analysis.
Lin Linni, Ren Yijie, Wang Xia et al. · Oral Dis · 2025
PMID: 40326505Meta-Analysis
Efficacy of denosumab in treatment of osteoporosis in patients with rheumatoid arthritis: a meta-analysis of randomized controlled trial.
Tang Tao, Wan Bingwen, Zhang Alei et al. · BMC Musculoskelet Disord · 2025
PMID: 40335975Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Denosumab (substance)
SNOMED CT
446321003
UMLS CUI
C1690432
RxNorm CUI
993449
Labeler
CELLTRION USA, Inc.

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
38
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.